What the premium above trailing earnings is actually buying

When a corp dev team prices a dental acquisition, the premium paid above trailing earnings is justified by what the deal team believes the practice can produce once their systems are running. But that number is built from historical financials and seller conversations, with one being backward looking and the other coming from the person most incentivised to be optimistic. Neither tells you what the practice actually contains right now at the patient level, whether the revenue base is structurally sound or quietly softening, or whether the upside being priced is real and recoverable rather than assumed and unverified. The premium being paid is justified by future performance, but the data that actually speaks to future performance is not even in the diligence package.

At a more serious scale of 50 to 100 acquisitions a year with a PE mandate to show precise returns, that gap starts costing real money.

In a practice doing $1.5M in collections, a forensic PMS analysis can surface $150K to $300K in recoverable revenue that never appeared in the financials. Such as lapsed recall worth $80K to $150K, $60K to $120K of accepted treatment never scheduled, and 30 to 40% provider variance causing a $60K to $120K production gap. At a 6x multiple, $200K in recoverable revenue sitting unquantified in the PMS is $1.2M in enterprise value the deal team had no visibility into when they set the price.

Across 80 acquisitions at $200K average recoverable per location, that's $16M in patient-level revenue priced on assumptions, annually. So practices with less recoverable upside than assumed actually underperform their model and compress IRR. While practices with more were acquired without the precision to bid aggressively on what was justified. Both outcomes affect the returns the fund reports, the carry the investment team earns, and the mandate they receive for the next deployment cycle. Portfolio revenue growing in high single digits looks fine at the group level but the IRR on individual deals where the upside assumption was wrong does not.

What changes this is not adding another analyst to the diligence team. The PMS data requires a forensic methodology, deal-room formatting, and benchmark context that doesn't exist inside a standard corp dev process, which is exactly why no current diligence package includes it.

The Operational QoE runs post-LOI concurrent with the financial QoE. There's no timeline delay or friction. It's a deal-room document showing specific recoverable figures per category, dollar amounts, and the operational reasons behind each gap, so that the price the investment committee approves is built on what the practice actually contains, and the integration team starts executing on day 1 with a targeted plan rather than a standardized playbook.

Every acquisition priced without this layer is being approved on an incomplete picture. The groups that start building it into how they underwrite will reduce risk and price with a precision others cannot match.